Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biosimilars | Current Treatment | Oncology | US/EU | 2019

Login to access report north_east
Contact sales account_box

In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb) biosimilars launched in the United States. Between mid-2018 and early-2019, trastuzumab biosimilars (Herzuma, Ontruzant, Kanjinti, Trazimera, and Ogivri)  expanded the biosimilar sector of the European oncology market. Uptake of these MAb biosimilars and biosimilars of granulocyte colony-stimulating factor (G-CSF) and erythropoiesis-stimulating agent (ESA) biosimilars will depend on the prescribing behavior of oncologists. To help manufacturers/marketers of oncology biosimilars and brands understand the opinions, actions, and expectations of these physicians, Decision Resources Group has conducted primary market research with oncologists in France, Germany, and the United States on the use of branded drugs versus their biosimilar competitors.

Questions answered:

  • What is the current patient share of oncology biosimilars, and what expectations do oncologists have for future patient shares, assuming additional biosimilars launch?
  • How similar do oncologists believe biosimilars are to their reference brands?
  • What factors do oncologists identify as being the key drivers and barriers to biosimilar uptake?
  • What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
  • What cost reduction is required for a biosimilar to achieve more than a 50% patient share?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Accord Healthcare
  • Amgen
  • Biogen
  • Bristol-Myers Squibb
  • Celltrion
  • Genentech
  • Merck
  • Novartis
  • Pfizer
  • Procrit
  • Sandoz
  • STADA
  • Roche
  • Teva

Key drugs mentioned:

  • Aranesp
  • Avastin
  • Binocrit
  • Epogen
  • Eprex
  • Erbitux
  • Erypo
  • Fulphila
  • Granix
  • Herceptin
  • Herzuma
  • Kanjinti
  • Lonquex
  • Mvasi
  • NeoRecormon
  • Neulasta
  • Neupogen
  • Nivestim/Nivestym
  • Ontruzant
  • Perjeta
  • Retacrit
  • Rituxan/MabThera
  • Rixathon
  • Silapo
  • Trazimera
  • Truxima
  • Udenyca
  • Vectibix
  • Yervoy
  • Zarzio/Zarxio
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
north_east
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east